Evidence map›Paper›PMID 23884313›Full record

ArticleThe Journal of investigative dermatology2014

MicroRNA-203 regulates melanosome transport and tyrosinase expression in melanoma cells by targeting kinesin superfamily protein 5b.

Shunsuke Noguchi, Minami Kumazaki, Yuki Yasui, Takashi Mori, Nami Yamada, Yukihiro Akao

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Targeting microRNA for improved skin health.Health science reports · 2021
    Review
  17. Article
  18. Review
  19. Article
  20. Exosomes: Emerging Diagnostic and Therapeutic Targets in Cutaneous Diseases.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shunsuke NoguchiUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan. Electronic address: snoguchi@gifu-u.ac.jp.
Minami KumazakiUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan; Graduate School of Engineering, Gifu University, Gifu, Japan.
Yuki YasuiUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan; Graduate School of Engineering, Gifu University, Gifu, Japan.
Takashi MoriDepartment of Veterinary Clinical Oncology, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan.
Nami YamadaUnited Graduate School of Veterinary Medical Sciences, Gifu University, Gifu, Japan.
Yukihiro AkaoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Gifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miR)-203 is known to be downregulated and to act as an anti-oncomir in melanoma cells. At present, we found that exogenous miR-203 increased pigmentation and protein expression levels of the melanoma antigen recognized by T cells (Melan-As/MART1s) and/or tyrosinase (TYR) in the human melanoma cells tested. Inversely, treatment with an inhibitor of miR-203 downregulated the expression level of TYR. The target gene of miR-203 involved in the mechanism was kinesin superfamily protein 5b (kif5b), which was revealed by gene silencing using short interfering RNA and luciferase activity assay. Furthermore, immunocytochemistry showed obvious accumulation of melanosomes around nuclei of human melanoma Mewo cells transfected with miR-203 or siR-kif5b. Importantly, treatment with the miR-203 inhibitor, but not miR-203, exhibited effects on human epidermal melanocytes isolated from lightly pigmented adult skin similar to those on melanoma cells. In addition, the data indicated that exogenous miR-203 also negatively regulated the cAMP response element-binding protein 1 (CREB1)/microphthalmia-associated transcription factor (MITF)/Rab27a pathway, which is one of the main pathways active in melanoma cells. In conclusion, our data indicated that anti-oncogenic miR-203 had a pivotal role in melanoma through reducing melanosome transport and promoting melanogenesis by targeting kif5b and through negative regulation of the CREB1/MITF/Rab27a pathway.

Indexed as

MelanomaSkin NeoplasmsBiological TransportCell Line, TumorCell ProliferationEpidermal CellsHumansKinesinsMelanocytesMelanosomesMicroRNAsMonophenol MonooxygenaseMyosin Heavy ChainsMyosin Type VRNA, Small InterferingSignal TransductionKIF2A protein, humanKIF5B protein, humanKinesinsMicroRNAsMIRN203 microRNA, humanMonophenol MonooxygenaseMYO5A protein, humanMyosin Heavy ChainsMyosin Type VRNA, Small Interfering

Identifiers

PMID23884313
OpenAlexW1984811431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.